Drug intelligence / Profile preview

SB424323 + aspirin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Buccal, Oral

Overview

SB424323 + aspirin is a combination investigational drug regimen composed of SB424323 (known as odiparcil) and aspirin. SB424323/odiparcil is a small molecule anti-thrombotic agent, developed as a modified-release tablet for buccal administration[3]. Aspirin is a widely used antiplatelet agent and anti-inflammatory analgesic. The combination aims to enhance antithrombotic activity by targeting complementary pathways in blood clot prevention: odiparcil via glycosaminoglycan modulation and aspirin by inhibiting platelet aggregation. This regimen has been studied in at least one completed clinical trial sponsored by Glaxo SmithKline[3].

Other names: odiparcil + aspirin

Targets

B4GALT7 (Beta-1,4-galactosyltransferase 7)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on SB424323 + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB424323 + aspirin.

Explore the full profile